Literature DB >> 19822154

Modeling the transmission dynamics and control of hepatitis B virus in China.

Lan Zou1, Weinian Zhang, Shigui Ruan.   

Abstract

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV) and is a major global health problem. HBV is the most common serious viral infection and a leading cause of death in mainland China. Around 130 million people in China are carriers of HBV, almost a third of the people infected with HBV worldwide and about 10% of the general population in the country; among them 30 million are chronically infected. Every year, 300,000 people die from HBV-related diseases in China, accounting for 40-50% of HBV-related deaths worldwide. Despite an effective vaccination program for newborn babies since the 1990s, which has reduced chronic HBV infection in children, the incidence of hepatitis B is still increasing in China. We propose a mathematical model to understand the transmission dynamics and prevalence of HBV infection in China. Based on the data reported by the Ministry of Health of China, the model provides an approximate estimate of the basic reproduction number R(0)=2.406. This indicates that hepatitis B is endemic in China and is approaching its equilibrium with the current immunization program and control measures. Although China made a great progress in increasing coverage among infants with hepatitis B vaccine, it has a long and hard battle to fight in order to significantly reduce the incidence and eventually eradicate the virus.

Entities:  

Mesh:

Year:  2009        PMID: 19822154     DOI: 10.1016/j.jtbi.2009.09.035

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  32 in total

1.  Optimal control for an age-structured model for the transmission of hepatitis B.

Authors:  Ramses Djidjou Demasse; Jean-Jules Tewa; Samuel Bowong; Yves Emvudu
Journal:  J Math Biol       Date:  2015-12-16       Impact factor: 2.259

2.  Too much of a good thing? When to stop catch-up vaccination.

Authors:  David W Hutton; Margaret L Brandeau
Journal:  Med Decis Making       Date:  2013-07-15       Impact factor: 2.583

3.  Clinical characteristics and current management of hepatitis B and C in China.

Authors:  Yong-Tao Sun; Yue-Xin Zhang; Hong Tang; Qing Mao; Xiao-Zhong Wang; Ling-Yi Zhang; Hong Chen; Ying-Na Zhong; Shu-Mei Lin; Da-Zhi Zhang
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

4.  Regional differences of hepatitis B discrimination in rural China.

Authors:  Jun Li; Jian Wang; Stephen Nicholas; Elizabeth Maitland; Teng Fei
Journal:  Hum Vaccin Immunother       Date:  2021-01-26       Impact factor: 3.452

5.  Development of a new duplex real-time polymerase chain reaction assay for hepatitis B viral DNA detection.

Authors:  Shipeng Sun; Shuang Meng; Rui Zhang; Kuo Zhang; Lunan Wang; Jinming Li
Journal:  Virol J       Date:  2011-05-14       Impact factor: 4.099

6.  Time-series analysis of hepatitis A, B, C and E infections in a large Chinese city: application to prediction analysis.

Authors:  A Sumi; T Luo; D Zhou; B Yu; D Kong; N Kobayashi
Journal:  Epidemiol Infect       Date:  2012-07-20       Impact factor: 4.434

7.  Modeling and Analyzing the Transmission Dynamics of HBV Epidemic in Xinjiang, China.

Authors:  Tailei Zhang; Kai Wang; Xueliang Zhang
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

8.  A numerical and analytical study of SE(Is)(Ih)AR epidemic fractional order COVID-19 model.

Authors:  Hasib Khan; Razia Begum; Thabet Abdeljawad; M Motawi Khashan
Journal:  Adv Differ Equ       Date:  2021-06-15

9.  Analysis of fractional COVID-19 epidemic model under Caputo operator.

Authors:  Rahat Zarin; Amir Khan; Abdullahi Yusuf; Sayed Abdel-Khalek; Mustafa Inc
Journal:  Math Methods Appl Sci       Date:  2021-03-25       Impact factor: 3.007

10.  Transmission model of hepatitis B virus with the migration effect.

Authors:  Muhammad Altaf Khan; Saeed Islam; Muhammad Arif; Zahoor ul Haq
Journal:  Biomed Res Int       Date:  2013-06-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.